Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

BACK TO CBER — Dr. Vinay Prasad has returned to the FDA’s Center for Biologics Evaluation and Research, leaving industry and ...

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency.

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...

Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...

Vor Bio appoints Dallan Murray as chief commercial officer, leveraging his extensive experience to drive commercialization ...

FDA reinstates Vinay Prasad to lead CBER as gene therapy safety concerns spotlight regulatory challenges in biotech manufacturing.

Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...